Verberk, Inge M. W.

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

Janelidze, S., Teunissen, C. E., Zetterberg, H., Allué, J. A., Sarasa, L., Eichenlaub, U., Bittner, T., Ovod, V., Verberk, I. M. W., Toba, K., et al. (2021) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 494

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

Chatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 439

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes

Verberk, I. M. W., Slot, R. E., Verfaillie, S. C. J., Heijst, H., Prins, N. D., van Berckel, B. N. M., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2018) · Annals of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 315

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 258

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project

Ebenau, J. L., Timmers, T., Wesselman, L. M. P., Verberk, I. M. W., Verfaillie, S. C. J., Slot, R. E. R., van Harten, A. C., Teunissen, C. E., Barkhof, F., van den Bosch, K. A., et al. (2020) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 191

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau

Janelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., et al. (2022) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 188

Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study

van der Ende, E. L., Meeter, L. H., Poos, J. M., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., Papma, J. M., de Jong, F. J., Verberk, I. M. W., Teunissen, C., et al. (2019) · The Lancet Neurology

Amyotrophic Lateral Sclerosis ResearchDementia and Cognitive Impairment Research

Cited by 181

Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score

Ebenau, J. L., van der Lee, S. J., Hulsman, M., Tesi, N., Jansen, I. E., Verberk, I. M. W., van Leeuwenstijn, M., Teunissen, C. E., Barkhof, F., Prins, N. D., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 26

The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease

Das, S., van Engelen, M.-P. E., Goossens, J., Jacobs, D., Bongers, B., Fieldhouse, J. L. P., Pijnenburg, Y. A. L., Teunissen, C. E., Vanmechelen, E., & Verberk, I. M. W. (2024) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 12